AbbVie Inc. is 75.7x more valuable than Apellis Pharmaceuticals, Inc. by market capitalization ($397.44 B vs $5.25 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | APLS | ABBV |
|---|---|---|
| Market cap | $5.25 B | $397.44 B |
| US-listed rank | #1353 | #28 |
| Revenue (latest FY) | $1.00B | $61.16B |
| Net income (latest FY) | $22.39M | $4.23B |
| Net margin | 2.2% | 6.9% |
| P/E (trailing FY) | 234.6 | 94.0 |
| SEC filings | 1,217 | 1,008 |
AbbVie Inc. is 75.7x more valuable than Apellis Pharmaceuticals, Inc. by market capitalization ($397.44 B vs $5.25 B).
In their latest fiscal years, Apellis Pharmaceuticals, Inc. reported $1.00B in revenue while AbbVie Inc. reported $61.16B.
Full pages: Apellis Pharmaceuticals, Inc. and AbbVie Inc., or browse the full rankings.